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Abstract—Herein is described the synthesis of several analogs of the natural product IB-01211 from concatenated azoles, via a biomimetic 
pathway based on cyclization-oxidation of serine containing peptides combined with the Hantzsch synthesis. The macrocyclization of rigid 
peptide compounds 1 and 2 to give IB-01211 and its epimer 12b was explored, and the results are compared here to those previously 
obtained for the macrocyclization of more flexible structures in the syntheses of YM-216391, telomestatin, and IB-01211. Lastly, the 
preliminary results of anti-tumor activity screening of the synthesized analogs are discussed.  © 2013 Elsevier Science. All rights reserved 
——— 
 Corresponding author. Tel.: +34 93 403 7086; fax: +34 93 403 7126; e-mail: albericio@pcb.ub.es; malvarez@pcb.ub.es. 
 
1. Introduction 
Directly-linked 2,4-azoles are found in natural products 
that have interesting biological activities and fascinating 
structures.  Numerous bis- and tris-oxazoles, as well as a 
few oxazole-thiazoles, have been isolated from marine 
organisms, whereas linked thiazole-containing natural 
products have generally been obtained from 
microorganisms.1  Marine organism secondary 
metabolites such as ulapualides,2 halichondramides,3 
kabiramides,3 mycalolides,4 halishigamides,5 and 
jaspisamides,6 all contain a trisoxazole fragment. These 
compounds show a broad range of unusual biological 
activities.7   
Telomestatin, a potent telomerase inhibitor isolated from 
Streptomyces anulatus 3533-SV48 that interacts 
specifically with the human telomeric intramolecular G-
quadruplex without affecting DNA polymerases or 
reverse transcriptases, contains a novel macrocyclic 
structure comprised of seven linked oxazoles and one 
thiazoline unit. A related cyclopeptides, YM-216391, 
containing only four oxazoles and one thiazole, has been 
isolated from Streptomyces nobilis.9   
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Figure 1. Natural compounds with 2,4-concatenated azoles
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Scheme 1.  Macrocyclization  in the syntheses of  YM-
216391, tetomestatin, and IB-01112 
A more recently discovered macrocyclic peptide, IB-
01211 (Figure 1), has been isolated from the marine-
derived microorganism strain ES7-008, which is 
phylogenetically close to Thermoactinomyces genus.10,11 
It is strongly cytotoxic against several tumor cell lines,12 
and contains four oxazoles and one thiazole. 
Concatenated azoles have been prepared following several 
strategies,1c including cyclodehydration of peptides 
containing serine, threonine or cysteine followed by 
oxidation of the azoline to azole; the classical Hantzsch 
synthesis allowing a one-pot synthesis of the azole-ring;  
Pd(0) catalyzed cross-coupling reaction—despite 
difficulties in the preparation of several precursors; 
sequential [3 + 2] cycloaddition of an appropriate 
rhodium carbene with nitriles, a new route to 
polyoxazoles from an ulapualide fragment; sequential 
Chan-type rearrangements of tertiary amides for the 
preparation of trisoxazoles; and finally, iterative oxazole 
assembly via base-promoted cyclization of alkynyl 
glycine derivatives prepared from the corresponding -
chloroglycinates by reaction with alkynyl dimethyl-
aluminum reagents. The total syntheses of YM-216391,13 
telomestatin,14 and IB-0121115 have recently been 
described. The three procedures possess a common 
feature, a macrocyclization of flexible precursors (Scheme 
1).  
The key step in the aforementioned synthesis of IB-01211 
is macrocyclization by Hantzsch formation of the thiazole 
ring. Alternatively, the macrocyclization could be 
envisaged through formation of an amide bond between 
penta-azole peptides 1 and 2 as the last synthetic step (see 
Figure 2). Thus, with the aim of synthesizing IB-01211 
and related derivatives, we studied the macrocyclization 
of penta-azole containing peptides. We describe here the 
preparation of several open chain IB-01211 derivatives, 
including subsequent macrocyclization studies and anti-
tumor activity screening. 
Results and Discussion 
 
Figure 2  Retrosynthetic analysis of IB-01211 
The retro-synthetic strategy used for this work is shown in 
Figure 2. Disconnection of the amide bonds between the 
D-Val and the aminoethylidene (disconnection a), or 
between the D-Allo-Ile and the phenyloxazolcarbonyl 
(disconnection b), affords the penta-azolepeptides 1 or 2, 
respectively.  Both peptides possess a tert-butyl protected 
alcohol, which can be readily transformed into the 
exocyclic methylidene present in the natural compound.  
The strategy involving intermediate 1 was thought to be 
more favorable than that with 2, which involves a 
coupling reaction of a hindered -amine and a poorly 
reactive carboxylic group.  A less convergent strategy 
through amide bond formation between the hindered Ile 
and Val residues was rejected.  The common precursors 
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for both azole-peptides are the penta-azole 3 and the 
dipeptide 4.  Finally, assembly of the middle thiazole 
present in compound 3 was planned from appropriately 
functionalized bisoxazoles 5 and 6.   
Synthesis of penta-azole 3 
Preparation of 3 was attempted by transformation of 
peptide 7a into thioamide 7b, followed by cyclization and 
oxidation (Scheme 2A).16  Reaction of the acid 5a and the 
amine 6a using the general procedure described in the 
experimental section for peptide bond formation afforded 
7a in good yield.17  The bis-oxazole derivative 5a was 
obtained by cyclization of the proper Ser peptide followed 
by oxidation of the resulting oxazolines, as previously 
described by our group.15  However, reaction of 7a with 
the Lawesson reagent to produce the thioamide 7b gave a 
complex mixture from which no product could be 
isolated.   
After exploring a broad range of reagents and conditions 
to afford the thiazole moiety, including the use of a 
cysteine-containing building block,18 we took a major 
shift in strategy: a classical Hantzsch synthesis using a 
thioamide and an -bromoketone (Scheme 2B). 
Bisoxazole 10, containing the protected -bromoketone 
residue for the Hantzsch synthesis, was obtained by two 
sequential oxazole-ring formations in order to minimize 
the amount of byproduct resulting from water elimination, 
and also because formation of a conjugated carbon-carbon 
double bond is favored by the presence of the phenyl ring.  
Cyclization and oxidation of dipeptide 819 afforded an 
oxazole with a protected amino ethanol-substituent at 
position 2 of the ring, which was then deprotected with 
95% trifluoroacetic acid (TFA)  to give the amino alcohol 
9.  Compound 9 was used in the following amide bond 
formation by reaction with bromopyruvic acid dimethyl 
acetal.  Subsequent ring closure and oxidation then 
provided 10.   Elimination of the acetal protecting group 
of 10 by treatment with formic acid at reflux gave the 
bromoketone 6b in quantitative yield.  Penta-azole 3 was 
obtained in a 62% yield by Hantzsch thiazole synthesis 
using the bis-oxazolethioamide 5b and the bis-oxazolyl -
bromomethyl ketone 6b.  It was characterized by 1H-
NMR, whereby the four singlets in the aromatic region, 
and the five aromatic protons, were taken as 
representative signals.   
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Peptides 4 and 4a were synthesized in solution from Boc-
D-allo-Ile-OH and H-Val-OMe, and from Boc-D-Ile-OH 
and H-Val-OMe, respectively, using EDC·HCl/HOBt and 
DIEA as coupling reagents. The N-deprotected and C-
deprotected peptides were obtained by TFA treatment and 
by methyl ester hydrolysis, respectively.  With penta-
azole 3 and epimeric peptides 4 and 4a in hand, we 
considered two options for macrocyclization, both of 
which implied preparation of peptides 1 and 2 (Scheme 
3).  The macrocyclization studies were performed with 
4a, as it is the cheaper of the two peptides. 
 
Compound 1a was prepared in good yield by methyl ester 
hydrolysis of 3 with LiOH, followed by condensation 
with N-deprotected-4a using EDC·HCl and HOBt as 
activating agents, and N,N-diisopropylethylamine (DIEA).  
In parallel, 2a was also obtained with good yields, by N-
and O-deprotection of 3 with 95% TFA, followed by 
condensation with the acid obtained in the saponification 
of 4a, as described above.  C- and N-deprotection of the 
linear precursors 1a (R1 = Me, R2 = Boc) and 2a (R1 = 
Me, R2 = Boc) were obtained in situ by methyl ester 
hydrolysis with LiOH followed by TFA treatment.  
Several macrocyclization trials were performed from C- 
and N-deprotected 1a (R1 = R2 = H) using the following 
activating agents: 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b] pyridinium hexafluorophosphate 3-
oxide (HATU)/N-methylmorpholine (NMM), 
HATU/DIEA,12 (benzotriazol-1-
yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate 
(PyBOP)/HOBt/DIEA, and (7-azabenzotriazol-1-
yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate 
(PyAOP)/DIEA.  No traces of cyclized compound were 
detected by either 1H-NMR or MS.  Likewise, no sign of 
12b was detected when the same cyclization conditions 
were applied to the methylidene derivative 11 (R1 = R2 = 
H), obtained by dehydration of 2a (R1 = Me, R2 = Boc) 
with mesyl chloride (MsCl) in Et3N followed by 
deprotection.  Finally, macrocyclization of 1a (R1 = R2 = 
H) was achieved using pentafluorophenol (PfpOH) as 
activating agent.  Thus, methyl ester hydrolysis of 1a (R1 
= Me, R2 = Boc), conversion of the resulting acid into the 
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pentafluorophenyl ester, N-deprotection20 and, finally, 
macrocyclization by treatment with DIEA in a highly 
diluted THF solution gave the cyclic peptide 12a (Scheme 
3).   
The exocyclic methylidene of 12b was prepared by O-
deprotection and dehydration of 12a using mesyl chloride 
as activating agent and N,N,N-triethylamine (TEA) in 
THF.  It was characterized by 1H-NMR, whereby the two 
methylidene singlets at 6.06 and 6.70 ppm, and the four 
singlets of the azole rings (7.96, 8.20, 8.27, and 8.30 
ppm), were taken as representative signals.21 As the yield 
of this macrocyclization was poor (less than 10%), we 
decided to test cyclization using a copper salt template. 
The peptide-heterocycle 1 (R1 = Me, R2 = Boc) was 
obtained by condensation of the free carboxylic acid of 3 
with the free amine of 4, using the same reaction 
conditions described above for 1a.  Similar conditions 
were also used for the methyl ester hydrolysis of 1, 
conversion of the resulting acid into the 
pentafluorophenyl ester followed by selective N-
deprotection. Macrocyclization was then attempted using 
DIEA and CuSO4 in a highly dilute THF solution. 
Unfortunately, no trace of the cyclized product was found, 
and only the pentafluorophenyl ester 13 of the open chain 
peptide-heterocycle was obtained. 
Biological activity 
The cytotoxicity of the concatenated azoles was evaluated 
against a panel of three human tumor cell lines: A-549 
lung carcinoma NSCL, HT-29 colon carcinoma, and 
MDA-MB-231 breast adenocarcinoma.  A conventional 
colorimetric assay was run to estimate GI50 values (i.e. the 
drug concentration at which 50% of cell growth is 
inhibited after 72 hours of continuous exposure to the test 
molecule), in which IB-01211 was for comparison. 
The results obtained are shown in Table 1.  A decrease of 
activity of compounds 3,  1, and 13 in relation with IB-
01211 has been observed.  Penta-azole 3 possess activity 
at micromolar (M) concentration in the three cell lines, 
whereas 1 possess the same activity only in A-549 and 13 
is inactive. The natural compound, IB-01211, shows 
activity in the three lines at nanomolar concentration.  
None of the peptides with D-Ile, 2a, 12a, and 12b, has 
notable activity. These results demonstrate the importance 
of the configuration of the stereocenter to the activity of 
these compounds. 
 
Table 1 .  Cell growth inhibition (GI50 ) of synthetized 
azoles. 
 
Cytotoxicity (GI50 M) 
 
Compound A-549a HT-29b MDA-MB-231c 
 
IB-01211 
 
0.06 
 
0.10 
 
0.069 
1d 4.92 n.a n.a 
1a d 9.84 6.78 n.a 
2a d n.a 10.1 n.a 
3  5.98 4.55 6.26 
12a n.ad n.ad n.ad 
12b n.ad n.ad n.ad 
13 n.ad n.ad n.ad 
a: A-549 lu n g ca r c i n o ma  NSCL;  b: HT-29 c o lo n  ca r ci n o ma  
cells;  c: MDA-MB-231 b r ea st  a d e n o ca r c in o ma ; d: n.a. = not 
active at 10 g/mL; d: R1 = Me, R2 = Boc 
Conclusions 
Herein we have reported preparation of the functionalized 
polyazoles 6a, 6b, 7a, the penta-azole 3, and the peptide-
heterocycles 1, 1a, 2a, 12a, 12b, and 13. Attempts at 
macrocyclization using the amino acids from the 
deprotection of 1 and 2 only led to a small amount of 
cyclized product, underscoring the need to change the 
synthetic strategy. Likewise, macrocyclization of N- and 
C-deprotected 1 using a copper chelating group also 
failed. While 1 and 2 possess an almost planar 
polyheterocyclic system of penta-azoles that separate the 
reactive groups the shown precursor of IB-01211 posses 
bigger conformational freedom which made the 
macrocyclization easier.   
The open chain polyazoles with the same stereocenter 
configuration as the natural product inhibit growth of 
human carcinoma cells (GI50) at micromolar 
concentrations, whereas the epi-analogs obtained with D-
Ile are inactive. 
Experimental section 
General. Melting points (m. p.) were determined in a 
Büchi Melting Point B540 in open capillaries and are 
uncorrected.  Reversed-phase analytical HPLC was 
performed on a Waters Alliance separation module 2695 
using a Waters Xterra MS C18 column (150 x 4.6 mm, 5 
m) and a Waters 996 PDA with a photodiode array 
detector with MeCN (0.036% TFA) and H2O (0.045% 
TFA).  Sonication was performed in a Branson ultrasound 
bath. Polarimetry studies were performed in a Perkin 
Elmer 241 polarimeter.  1H NMR and 13C NMR spectra 
were recorded on a Varian Mercury 400 MHz and Varian 
500 MHz spectrometers. Multiplicity of the carbons was 
assigned with DEPT and gHSQC experiments. Usual 
abbreviations for off-resonance decoupling have been 
used here: (s) singlet, (d) doublet, (t) triplet, and (q) 
quartet.  The same abbreviations have also been used for 
the multiplicity of signals in 1H-NMR, plus: (m) multiplet, 
(dd) double doublet, (bs) broad singlet, and (bd) broad 
doublet.  Spectra were referenced to appropriate residual 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 Tetrahedron 6
solvent peaks (CDCl3 and d6-DMSO). CI-MS were 
measured in a Hewlett-Packard model 5890A with 
ammonia (NH3). MALDI-TOF and ES-MS were 
performed in a PerSeptive Biosystems Voyager DE RP, 
using an ACH matrix, for the former, and a Waters 
alliance 2795 HPLC equipped with a 2487 UV-Vis 
detector and coupled to a ZQ electrospray mass detector, 
for the latter.  The samples were run with MeCN (0.07% 
HCO2H) and H2O (0.1% HCO2H).  HRMS were 
performed on a Bruker Autoflex high resolution mass 
spectrometer by the Mass Spectrometry Service of the 
University of Santiago de Compostela.1 
Syntheses of compounds 4 ([]D +22.3 (c 0.56, CHCl3), 
5a, 5b, 8, 9, and 10 have previously been reported.15  
Peptide bond formation.  Sample procedure:  
D-Boc-Ile-L-Val-OMe (4a)  D-Boc-Ile-OH. ½ H2O (795 
mg, 3.31 mmol), EDC•HCl (698 mg, 3.64 mmol), HOBt 
(491 mg, 3.64 mmol), and DIEA (1.21 mL, 7.11 mmol) 
were added to a solution of L-H-Val-OMe•HCl (550 mg, 
3.31 mmol) and dry CH2Cl2 (28 mL) at 0 ºC.  The mixture 
was stirred at room temperature for 20 h. The organic 
solution was washed with 5% NaHCO3 and NH4Cl, dried 
and concentrated to give the title compound (1.02 g, 90%) 
as a white solid, m. p. 105-107 ºC.  []D +16.6 (c 0.7, 
CHCl3). 1H NMR (CDCl3, 400 MHz)  0.88-0.93 (m, 
12H); 1.09-1.21 (m, 1H); 1.42 (s, 9H); 1.49-1.55 (m, 1H); 
1.86 (m, 1H); 2.11-2.20 (m, 1H); 3.72 (s, 3H); 3.92-3.95 
(m, 1H); 4.51-4.55 (m, 1H); 5.04-5.06 (d, 6.8 Hz, 1H); 
6.37-6.39 (d, 6.8 Hz, 1H). 13C NMR (CDCl3, 100 MHz)  
11.31 (q); 15.5 (q); 17.71 (q); 18.9 (q); 24.78 (t); 28.27 
(q); 31.20 (d); 36.91 (d); 52.09 (q); 57.01 (d); 59.37 (d); 
79.88 (s); 155.73 (s); 171.55 (s); 172.08 (s). MS (CI): m/z 
345 (M + 1, 100), 289 (M, 29), 245 (M, 43). HRMS m/z 
calcd. for C17H32N2NaO5 (M + Na) 367.2203, found 
367.2206.  
Hydrolysis of methyl esters 2M LiOH (9 mmol) was 
added to a solution of methyl ester (3 mmol) in THF-H2O-
MeOH (50:6:0.2, 14 mL), and the reaction mixture was 
stirred at room temperature for 1 h.  The pH of was 
brought to 3 by addition of 1M HCl, and then the solution 
was extracted with EtOAc. The organic layer was dried 
over MgSO4 and concentrated to afford the acid as a white 
solid.  
Deprotection with TFA 
Method A.  Elimination of N-Boc and O-tert-Bu 
protecting groups. 95% TFA (5 mL) was added to a 
solution of the di-protected (N-Boc and O-tert-Bu) 
compound (2.38 mmol), and the solution was stirred at 
room temperature for 5 h.  The TFA was then removed 
——— 
 
under reduced pressure, and the crude material was used 
for subsequent chemistry without further purification. 
Method B. Selective elimination of N-Boc protecting 
group. A solution of N-Boc protected compound (27 
mol) in TFA-CH2Cl2 (1 mL, 3:7) was stirred at room 
temperature for 1 h. The TFA and the solvent were 
removed, and the crude material was used for subsequent 
chemistry without further purification. 
Peptide 1 (R1 = Me, R2 = Boc). Coupling of the free 
carboxylic acid of 3 to the free amine of 4 using the 
general procedure for peptide formation provided 1 (70%) 
as a white solid, m. p. (MeCN) 186-188 ºC. []D +4.0 (c 
0.56, CHCl3).  1H NMR (CDCl3, 400 MHz)  0.88-1.08 
(m, 12H); 1.12 (s, 9H); 1.22-1.34 (m, 1H); 1.48 (s, 9H); 
1.52-1.62 (m, 1H);  2.11-2.25 (m, 2H); 3.70 (s, 3H); 3.74 
(dd, J= 4.4, 9.2 Hz, 1H); 4.57 (dd, J= 5.2 Hz and 8.6 Hz, 
1H); 4.65 (dd, J= 5.6 Hz and 8.8 Hz, 1H); 5.06-5.14 (m, 
1H); 5.62 (bs, 1H); 6.56 (bs, 1H); 7.42-7.53 (m, 3H), 7.81 
(bs, 1H); 8.24 (s, 1H); 8.29 (s, 1H); 8.33-8.38 (m, 2H); 
8.42 (s, 1H); 8.47 (s, 1H). 13C NMR (CDCl3, 100 MHz)  
11.6 (q); 14.7 (q); 17.8 (q); 18.9 (t); 27.3 (q); 28.3 (q); 
29.7 (t); 31.2 (d);  37.1 (d); 50.1 (d); 52.1 (q); 57.1 (d); 
57.2 (t); 62.9 (t); 73.7 (s); 80.2 (s); 122.0 (d); 126.6 (s); 
128.3 (d); 128.5 (d); 129.6 (s); 129.9 (s); 130.2 (d); 131.0 
(s); 136.2 (d); 136.3 (s); 139.3 (d); 143.4 (d); 151.9 (s); 
153.0 (s); 155.3 (s); 155.6 (s); 158.2 (s); 161.2 (s); 161.3 
(s); 164.8 (s); 171.0 (s); 172.0 (s). MS (MALDI): m/z 
937.33 (M + 23, 100). HRMS m/z calcd. for 
C45H54N8NaO11S (M + Na) 937.3525, found 937.3527.  
 
Peptide 1a (R1 = Me, R2 = Boc). Coupling of the free 
carboxylic acid of 3 to the free amine of 4a using the 
general procedure for peptide formation provided 1a 
(70%) as a white solid, m. p. (MeCN) 188-190 ºC. []D 
+3.4 (c 0.64, CHCl3).  1H NMR (CDCl3, 400 MHz)  
0.87-1.02 (m, 12H); 1.03-1.06 (m, 1H); 1.11 (s, 9H); 
1.21-1.33 (m, 1H); 1.47 (s, 9H); 1.60-1.75 (m, 1H); 2.07-
2.24 (m, 1H); 3.69 (s, 3H); 3.71-3.76 (m, 1H); 3.84-3.91 
(m, 1H); 4.47-4.61 (m, 2H); 5.04-5.14 (m, 1H); 5.60 (bs, 
1H); 6.50 (bs, 1H); 7.42-7.53 (m, 3H), 7.82 (bs, 1H); 8.23 
(s, 1H); 8.28 (s, 1H); 8.32-8.38 (m, 2H); 8.4 (s, 1H); 8.47 
(s, 1H). 13C NMR (CDCl3, 100 MHz)  11.4 (q); 15.7 (q); 
17.6 (q); 19.0 (q); 25.1 (t); 27.3 (q); 28.3 (q); 31.2 (d); 
36.9 (d);  50.1 (d); 52.1 (q); 57.2 (d); 58.1 (d); 62.9 (t); 
73.7 (s); 80.2 (s); 122.0 (d); 126.7 (s); 128.4 (d); 128.5 
(d); 129.7 (s); 130.0 (s); 130.2 (s); 131.1 (s); 136.2 (d); 
136.4 (s); 139.3 (d); 143.4 (d); 151.8 (s); 153.1 (s); 155.3 
(s); 155.6 (s); 158.2 (s); 161.1 (s); 161.2 (s); 164.8 (s); 
170.7 (s); 171.9 (s). (MALDI): m/z 937.31 (M + Na, 100). 
HRMS m/z calcd. for C45H54N8NaO11S (M+Na) 
937.3525, found 937.3529.   
 
Peptide-heterocycle 2a (R1 = Me, R2 = Boc).  The free 
amino-alcohol, obtained by N- and O-deprotection of 3 
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using 95% TFA (2 mL), was coupled to the acid of 4a 
following the general procedure for peptide formation to 
provide 2a (50 %) as a white solid,  m. p. (MeCN)  224-
226 ºC.  1H NMR (DMSO, 400 MHz)  0.76-0.88 (m, 
12H); 0.95-1.10 (m, 1H); 1.37 (s, 9H); 1.45-1.46 (m, 1H); 
1.63-1.72 (m, 1H); 1.94-2.06 (m, 1H); 3.57-3.63 (m, 1H); 
3.76-3.84 (m, 1H); 3.86 (s, 3H); 3.97-4.07 (m, 1H); 4.11-
4.17 (m, 1H); 5.14-5.21 (m, 1H); 5.30-5.36 (bs, 1H); 6.77 
(bs, 1H); 7.55-7.61 (m, 3H); 7.73-7.80 (bs, 1H); 8.06-8.11 
(m, 2H); 8.67 (s, 1H); 9.03 (s, 1H); 9.08 (s, 1H); 9.2 (s, 
1H).   1H NMR (DMSO, 400 MHz)  0.76-0.88 (m, 12H); 
0.95-1.10 (m, 1H); 1.37 (s, 9H); 1.45-1.46 (m, 1H); 1.63-
1.72 (m, 1H); 1.94-2.06 (m, 1H); 3.57-3.63 (m ,1H); 3.76-
3.84 (m, 1H); 3.86 (s, 3H); 3.97-4.07 (m, 1H); 4.11-4.17 
(m, 1H); 5.14-5.21 (m, 1H); 5.30-5.36 (bs, 1H); 6.77 (bs, 
1H); 7.55-7.61 (m, 3H); 7.73-7.80 (bs, 1H); 8.06-8.11 (m, 
2H); 8.67 (s, 1H); 9.03 (s, 1H); 9.08 (s, 1H); 9.2 (s, 1H). 
13C NMR (CDCl3, 100 MHz)  10.8 (q); 15.3 (q); 17.9 
(q); 19.0 (q); 29.0 (t); 29.8 (q); 36.27 (d); 40.6 (d); 50.2 
(d); 52.0 (q); 57.7 (d); 58.7 (d); 60.5 (t); 69.7 (s); 78.8 (s); 
123.4 (d); 126.1 (s); 127.2 (s); 128.2 (2d); 128.5 (2d); 
129.8 (s); 129.9 (s); 130.6 (d); 135.4 (d); 139.1 (s); 141.2 
(d); 141.3 (s); 141.5 (s); 142.6 (d); 152.8 (s); 154.3 (s); 
155.2 (s); 157.4 (s); 160.4 (s); 161.6 (s); 163.6 (s); 164.1 
(s); 172.6 (s). (MALDI): m/z 881.07 (M + Na, 78); 783 
(95); 759 (100). HRMS m/z calcd. for C41H46N8NaO11S 
(M + Na) 881.2899, found 881.2886. 
Methyl 2'-{2-[2'-(2-tert-butoxy-1-tert-butoxycarbonyl-
aminoethyl)-[2, 4']bis-oxazol-4-yl]thiazol-4-yl}-5-
phenyl[2,4']bis-oxazolyl-4-carboxylate (3) Bromoketone 
6b (64 mg, 0.16 mmol) was added to a suspension of 5b 
(45 mg, 0.11 mmol) and NaHCO3 (29 mg, 0.35 mmol) in 
THF (2 mL).  The mixture was stirred for 8 h at room 
temperature, at which point it was filtered over alumina 
and washed with CH2Cl2-MeOH (4:1). The organic layer 
was concentrated to give a crude material which was 
dissolved in dry THF (2 mL) and cooled to –10 ºC.  
Lutidine (0.10 mL, 0.87 mmol) and TFAA (46 L, 0.33 
mmol) were then added to the solution, and the reaction 
mixture was stirred at room temperature overnight. 
Concentration in vacuo gave a brown residue, which was 
purified by silica gel chromatography. Elution with 
CH2Cl2/EtOAc (9:1) gave 3 (47.8 mg, 62%) as a white 
solid, m. p. (MeCN) 216-218 ºC. []D –12.2 (c 0.51, 
CHCl3).  1H NMR (CDCl3, 400 MHz)  1.11 (s, 9H); 1.47 
(s, 9H); 3.73 (dd, J = 4.4 and 9.2 Hz, 1H); 3.86-389 (m, 
1H); 3.98 (s, 3H); 5.06-5.12 (m, 1H); 5.58-5.60 (d, J = 8.4 
Hz, 1H); 7.49-7.52 (m, 3H); 8.17-8.20 (m, 2H); 8.22 (s, 
1H); 8.28 (s, 1H); 8.46 (s, 1H); 8.49 (s, 1H). 13C NMR 
(CDCl3, 100 MHz)  27.29 (q); 28.32 (q); 29.69 (q); 
50.14 (s); 52.43 (d), 62.94 (t); 73.75 (s); 121.92 (d); 
126.46 (s); 127.68 (s); 128.44 (d); 128.66 (d); 129.95 (s); 
130.63 (s); 131.0 (s); 136.17 (d); 136.4 (s); 139.30 (s); 
139.37 (d); 143.51 (d); 153.03 (s); 155.61 (s); 158.01 (s); 
161.17 (s); 162.35 (s); 164.79 (s). MS (FAB): m/z 720.1 
(M + 18, 65), 589 (M + 1, 100). HRMS m/z calcd. for 
C34H34N6NaO9S (M + Na) 725.200, found 725.1993.  
Methyl 2'-(2-tert-butoxy-1-tert-butoxycarbonylamino-
ethyl)-5-phenyl[2, 4']bis-oxazolyl-4-carboxylate (6)  
The free amine of 9 was coupled with Boc-L-Ser(tBu)-
OH following the general procedure for peptide 
formation.  Cyclization using DAST/K2CO3 and oxidation 
with DBU-CCl4 in Pyr and ACN as solvents gave a crude 
which was purified by column chromatography on silica 
gel.  Elution with hexane/ EtOAc (3:1) gave 6 (50%) as a 
solid, m. p. (MeCN) 66-68 ºC. 1H NMR (CDCl3, 400 
MHz)  1.1 (s, 9H); 1.47 (s, 9H); 3.72 (dd, J = 4.0 and 9.2 
Hz, 1H); 3.83-3.89 (m, 1H); 3.96 (s, 3H); 5.02-5.12 (m, 
1H); 5.6 (bs, 1H); 7.45-7.51 (m, 3H); 8.10-8.15 (m, 2H); 
8.33 (s, 1H). 13C NMR (CDCl3, 100 MHz)  27.24 (q); 
28.30 (q); 50.10 (d); 52.32 (q); 62.89 (t), 73.70 (s); 80.13 
(s); 126.50 (s); 127.60 (s); 128.40 (2d); 128.56 (2d) 
129.80 (s); 130.50 (s); 139.41 (d); 153.31 (s); 155.34 (s); 
162.35 (s); 164.50 (s). MS (ES) m/z 486.53 (M + 1, 100). 
HRMS m/z calcd. for C25H32N3O7 486.2235, found 
486.2222.   
Methyl 2'-(2-bromoacetyl)-5-phenyl[2, 4']bis-oxazolyl-
4-carboxylate (6b). A mixture of 10 (200 mg, 452 mol) 
and formic acid (3.5 mL) was refluxed for 2 h, and then 
cooled to room temperature.  The organic solution was 
poured into an aqueous solution of NaHCO3 and extracted 
with CH2Cl2. The organic layer was dried over MgSO4 
and concentrated to give 6b (164 mg, 91%) as a yellow 
oil.  1H NMR (CDCl3, 400 MHz)  3.98 (s, 3H); 4.68 (s, 
2H); 7.51-7.53 (m, 3H); 8.13-8.16 (m, 2H); 8.58 (s, 1H).  
13C NMR (CDCl3, 100 MHz)  30.3 (t); 52.5 (q); 126.1 
(s); 127.8 (s); 128.5 (2d); 128.6 (2d); 130.9 (d); 131.7 (s); 
142.5 (d); 151.3 (s); 155.9 (s); 156.1 (s); 162.1 (s); 178.7 
(s). MS (ES): m/z 408.1 (MBr79 + 18, 61); 410.1 (MBr81 + 
18, 62); 391 (MBr79, 62); 393 (MBr81, 63); 313 (100). 
HRMS m/z calcd. for C16H12BrN2O5 390.9924, found 
390.9911. 
Peptide 7a.  The free carboxylic acid of 5 (40 mg, 0.10 
mmol) was coupled to 6a (33 mg, 0.10 mmol) using the 
general procedure for peptide formation to provide 7a (31 
mg, 43%) as a yellow solid, m. p. (MeCN) 98-100 oC.  
[]D –13.4 (c 0.35, CHCl3).  1H NMR (CDCl3, 400 MHz) 
 1.09 (s, 18H); 1.45 (s, 9H); 3.6-3.70 (m, 1H); 3.79-3.84 
(m, 1H); 3.93 (s, 3H); 4.09-4.13 (m, 1H); 4.28-4.32 (m, 
1H); 5.01-5.09 (m, 1H); 5.55-5.59 (m, 1H); 7.43-7.48 (m, 
4H); 7.95 (d, J = 8.0 Hz, 1H) 8.07-8.10 (m, 2H); 8.20 (s, 
1H); 8.26 (s, 1H); 8.33 (s, 1H).  13C NMR (CDCl3, 100 
MHz)  27.2 (q); 28.2 (q); 48.5 (d); 50.1 (d); 52.4 (q); 
62.9 (t); 63.2 (t); 73.7 (s); 80.3 (s); 126.6 (s); 127.8 (s); 
128.7 (d); 128.8 (d); 129.9 (s); 130.9 (d); 136.5 (s); 139.5 
(d); 140.2 (d); 141.8 (d); 153.0 (s); 153.6 (s); 155.6 (s); 
155.8 (s); 155.9 (s); 160.5 (s); 160.8 (s); 163.2 (s); 164.2 
(s); 171.3 (s). MS (MALDI-TOF) 745 (M + K); 729.24 
(M + Na, 100); 707.64 (60); 674 (60). HRMS m/z calcd 
for C34H38N6NaO11 (M + Na) 729.2491, found 729.2480.   
Peptide 12a. A solution of the carboxylic acid (125 mg, 
190 mol) obtained from 1a in dry THF-DMF (120 mL 
and 5 mL) was cooled to 0 ºC.  EDC·HCl (190 mg, 99 
mol), DIEA (167 L, 99 mol), and Pfp-OH (194 mg, 
1.05 mmol) were then added, and the mixture was stirred 
at room temperature for 20 h. The solvents were removed 
in vacuo, and the residue was diluted with CH2Cl2 and 
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washed with 5% aqueous NaHCO3 and aqueous NH4Cl. 
The organic solution was dried and concentrated, and the 
residue was diluted with TFA-CH2Cl2 (6 mL and 14 mL). 
The solution was stirred for 1 h at room temperature, and 
then the TFA was removed, and the crude material was 
dissolved in THF (250 mL). DIEA (479 L, 2.82 mmol) 
was added, and the mixture was stirred for 96 h at room 
temperature. The solvents were removed, and the residue 
was then washed with MeOH.  The residue obtained after 
removing the solvent was purified by preparative HPLC. 
A gradient of H2O (0.045% TFA) / MeCN (0.036% TFA) 
from 6:4 until 1:9 in 15 min  gave a white solid (10 mg, 
9%, rt = 7.47 min), m. p. (MeCN)  206-208 ºC.  []D –
48.3 (c 0.35, DMSO).  1H NMR (d6-DMSO, 500 MHz)   
0.82 -0.95 (m, 12H); 1.02-1.06 (m, 2H); 1.22 (s, 9H); 
1.49-1.57 (m, 1H); 1.85-1.91 (m, 1H); 3.85-3.94 (m, 1H); 
3.97-4.04 (m, 1H); 4.17-4.24 (m, 1H); 4.62-4.71 (m, 1H); 
5.16-5.21 (m, 1H); 5.28-5.35 (m, 1H); 7.53-7.58 (m, 3H); 
8.01 (bs, 1H); 8.03 (bs, 1H); 8.27-8.37 (m, 2H); 8.49 and 
8.62 (2bs, 1H); 8.73 (s, 1H); 9.04 (s, 1H); 9.12 (s, 1H);  
9.23 (s, 1H); 10.17 (bs, 1H).   13C NMR (d6-DMSO, 125 
MHz) 11.3 (q); 14.2 (q); 15.6 (q); 18.7 (q); 18.8 (q); 24.5 
(t); 38.1 (d); 50.5 (d); 56.5 (d); 57.7 (d); 60.9 (t); 67.8 (d); 
123.9 (d); 128.4 (2d); 128.9 (2d); 130.5 (d); 138.0 (d); 
141.8 (d); 141.9 (d). MS (MALDI): m/z 782.19 (M, 40). 
Peptide 12b.  Peptide 12a (9 mg, 0.0114 mmol) was 
deprotected with 95% TFA (1 ml). The crude was 
dissolved in dry THF (1 mL), and the solution was cooled 
to 0 ºC, TEA (15.82L, 0.114 mmol) and MsCl (4.4 L, 
0.057 mmol) were added drop-wise. The resulting 
solution was stirred for 2 h at 0º C, then washed with 
NH4Cl and water, dried, and concentrated.  The solvents 
were removed and the residue was washed with MeCN to 
give a white solid (7.4 mg, 90%), m. p. (MeCN) 147-149 
ºC. []D +12.4 (c 0.15, CHCl3).  1H NMR (CDCl3, 500 
MHz)  0.79-0.92 (m, 12H); 0.99-1.09 (m, 2H); 1.41-1.45 
(m, 1H); 1.52-1.55 (m, 1H); 3.65-3.75 (m, 2H); 3.78-3.89 
(m, 1H); 6.06 (s, 1H); 6.70 (s, 1H); 7.43-7.52 (m, 4H); 
7.96 (s, 1H); 8.20 (s, 1H); 8.27 (s, 1H); 8.30 (s, 1H); 8.31 
(bs, 1H); 8.36-8.37 (m, 2H); 8.47 (bs, 1H). 13C NMR 
(CDCl3, 125 MHz)  11.29 (q); 13.9 (q); 15.2 (q); 18.7 
(q); 25.2 (t); 30.2 (d); 30.7 (d); 53.6 (d); 63.2 (d); 111.7 
(t); 119.5 (d) ; (d); 127.9 (d) ; 128.4 (2d); 130.2 (2d); 
137.7 (d); 139.0 (d); 139.4 (d). MS (MALDI): m/z 749.3 
(M + Na, 100), 765.3 (M + K, 47). 
Peptide 13 A solution of carboxylic acid (150 mg, 0.166 
mmol) obtained from 1 in dry THF-DMF (10 mL and 2 
mL) was cooled to 0 ºC. EDC·HCl (0.22 mg, 1.16 mmol), 
DIEA (0.19 ml, 1.16 mmol) and Pfp-OH (0.229 mg, 1.24 
mmol) were then added, and the reaction mixture was 
stirred at room temperature for 20 h. The solvents were 
removed in vacuo, and the residue was diluted with 
CH2Cl2, and then washed with 5% aqueous NaHCO3 and 
aqueous NH4Cl. The organic solution was dried and 
concentrated, and the residue was diluted in TFA-CH2Cl2 
(1 mL/3 mL). The solution was stirred for 1 h at room 
temperature, and then the TFA was removed. The crude 
material was dissolved in THF (300 mL). DIEA (0.28 ml, 
1.66 mmol) and CuSO4 (132 mg, 0.83 mmol) were added, 
and the mixture was stirred for 72 h at room temperature. 
The solvents were removed, and the crude was purified by 
silica gel chromatography (9:1 CH2Cl2- MeOH) to give 13 
(58.8 mg, 37%) as a yellow solid, m. p. (MeCN) 140-142 
ºC. []D +7.7 (c 0.39, CHCl3).  1H NMR (CDCl3, 400 
MHz)  0.94-1.09 (m, 12H); 1.13 (s, 9H); 1.20-1.32 (m, 
1H); 1.51-1.61 (m, 1H); 2.08-2.26 (m, 1H); 2.32-2.43 (m, 
1H) 3.77-3.83 (m, 1H); 3.96-4.01 (m, 1H);  4.55-4.65 (m, 
1H); 4.82-4.91 (m, 1H); 5.38-5.45 (m, 1H); 6.67 (d, J= 
8.4 Hz, 1H); 6.81 (d, J= 8.4 Hz, 1H); 7.42-7.47 (m, 3H); 
8.24 (s, 1H); 8.29-8.30 (m, 2H); 8.31 (s, 1H); 8.40 (s, 
1H); 8.47 (s, 1H). 13C NMR (CDCl3, 100 MHz)  11.4 
(q); 14.7 (q); 17.6 (q); 18.9 (q); 26.2 (t); 27.3 (q); 30.9 (d); 
36.4 (d); 48.9 (d); 57.2 (d); 57.5 (d); 61.8 (t); 74.3 (s); 
122.3 (d); 125.1 (s); 126.4 (s); 126.5 (s); 128.3 (2d); 128.5 
(2d); 128.7 (s); 129.4 (s); 130.1 (s); 130.3 (d); 130.9 (s); 
131.5 (s); 136.3 (s); 136.4 (d); 139.3 (d); 139.8 (d); 143.3 
(s); 151.8 (s); 153.2 (s); 155.1 (s); 156.8 (s); 157.2 (s); 
158.2 (s); 161.0 (s); 161.5 (s); 162.0 (s); 167.7 (s); 171.5 
(s). 19F NMR (CDCl3, 400 MHz)  84.0 (s). (MALDI): 
m/z 1006.7 (M + K, 100).  
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